Contineum Therapeutics CTNM
NASDAQ CTNM
$10.84 -1.89 (-14.85%)
As of: Sep 29, 2026 · 3:50 PM EDT

Contineum Therapeutics (CTNM) EBITDA Margin (2023)

Updated

Contineum Therapeutics (CTNM) reported EBITDA Margin of 32.55% for FY2023.

Analysis

Contineum Therapeutics (CTNM) EBITDA Margin (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Contineum Therapeutics 476.97 Mn 476.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 77.96%
API Access

Contineum Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CTNM&period=max&api_key=YOUR_API_KEY